Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease‑modifying anti‑rheumatic drugs: A meta‑analysis of randomized controlled trials

Wu,Zhi‑Peng; Zhang,Pei; Bai,Jian‑Zhong; Liang,Yuan; He,Jin‑Shan; Wang,Jing‑Cheng

doi:10.3892/etm.2018.6495

Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease‑modifying anti‑rheumatic drugs: A meta‑analysis of randomized controlled trials

Authors:
- Zhi‑Peng Wu
- Pei Zhang
- Jian‑Zhong Bai
- Yuan Liang
- Jin‑Shan He
- Jing‑Cheng Wang
View Affiliations

Affiliations: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of Orthopedics, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu 225001, P.R. China
Published online on: July 20, 2018 https://doi.org/10.3892/etm.2018.6495
Pages: 2449-2459
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present meta‑analysis was to assess the efficacy and safety of baricitinib for active rheumatoid arthritis (RA) in patients with an inadequate response or intolerance to conventional synthetic or biological disease‑modifying anti‑rheumatic drugs (DMARDs). A total of 7 randomized controlled trials (RCTs) were included. The primary effective outcome was the RA improvement to reach an American College of Rheumatology 20% (ACR20) response rate. The safety outcomes were composed of clinical laboratory parameters. All patients included received 4 mg baricitinib once daily to treat RA for 12 or 24 weeks. The ACR20 response rate in the baricitinib group was significantly higher compared with that in the control group at 12 weeks [relative risk (RR), 1.77; 95% confidence interval (CI), 1.62‑1.94; P<0.00001] and 24 weeks (RR, 1.76; 95% CI, 1.48‑2.10; P<0.00001). Similarly, other effective outcome measures also exhibited significant improvements in the baricitinib group compared with those in the placebo group. Regarding the safety outcomes, no significant difference in adverse events (AEs) was identified at 12 weeks (P=0.14), but AEs were significantly higher in the baricitinib group compared with those in the control group at 24 weeks (P=0.03). Most laboratory values were significantly different between the baricitinib and placebo groups; however, the clinical significance of these changes remains to be determined. In summary, the present meta‑analysis demonstrated that 4 mg baricitinib once daily was beneficial in patients with active RA with an inadequate response or intolerance to conventional synthetic or biological DMARDs. More high‑quality RCTs are required to determine the sustained efficacy and the safety of baricitinib.

View Figures

View References

1	Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M and Kirwan J: Rheumatology outcomes: The patient's perspective. J Rheumatol. 30:880–883. 2003.PubMed/NCBI
2	Furst DE and Emer P: Rheumatoid arthritis pathophysiology: Update on emerging cytokine and cytokine-associated cell targets. Rheumatology. 53:1560–1569. 2014. View Article : Google Scholar : PubMed/NCBI
3	Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, et al: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study. Ann Rheum Dis. 76:88–95. 2017. View Article : Google Scholar : PubMed/NCBI
4	Kubo S, Nakayamada S and Tanaka Y: Baricitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 12:911–919. 2016. View Article : Google Scholar : PubMed/NCBI
5	Iwata S and Tanaka Y: Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 12:1047–1057. 2016. View Article : Google Scholar : PubMed/NCBI
6	Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
7	Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, et al: Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical characterization of INCB028050. J Immunol. 184:5298–5307. 2010. View Article : Google Scholar : PubMed/NCBI
8	Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV and Yeleswaram S: The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 54:1354–1361. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kubo S, Nakayamada S, Nakano K and Tanaka Y: THU0203 baricitinib targets the type I IFN/STAT-medicated activities of human T cells and dendritic cells. Ann Rheum Dis. 75 Suppl 2:S2602016. View Article : Google Scholar
10	Emery P, Mcinnes I, Genovese MC, Smolen JS, Kremer J, Dougados M, Schlichting DE, Rooney T, Issa M, Bono Sd, et al: A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies. Ann Rheum Dis. 75 Suppl 1:A622016. View Article : Google Scholar
11	Song GG, Bae SC and Lee YH: Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: A meta-analysis of randomized controlled trials. Korean J Intern Med. 29:656–663. 2014. View Article : Google Scholar : PubMed/NCBI
12	Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, et al: Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 7:412010. View Article : Google Scholar : PubMed/NCBI
13	Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group, : Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009. View Article : Google Scholar : PubMed/NCBI
14	Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:727–735. 1995. View Article : Google Scholar : PubMed/NCBI
15	Aletaha D and Smolen J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 23 5 Suppl 39:S100–S108. 2005.PubMed/NCBI
16	van Tuyl LH and Boers M: Patient's global assessment of disease activity: What are we measuring? Arthritis Rheum. 64:2811–2813. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bruce B and Fries JF: The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 23 Suppl 39:S14–S18. 2005.PubMed/NCBI
18	Higgins JP and Green S: Cochrane handbook for systematic reviews of interventions version 5.1.0. Naunyn-Schmiedebergs Archiv Für Exp Pathol und Pharmakol. 5:S382011.
19	Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, et al: Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 69:506–517. 2017. View Article : Google Scholar : PubMed/NCBI
20	Tanaka Y, Ishii T, Cai Z, Schlichting D, Rooney T and Macias W: Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. Mod Rheumatol. 28:20–29. 2018. View Article : Google Scholar : PubMed/NCBI
21	Takeuchi T, Genovese M, Xie L, Issa M, Pinto Correia AL, Rooney T, Emoto K and Smolen J: OP0228 baricitinib dose step-down following disease control in patients with rheumatoid arthritis. Ann Rheumat Dis:. 75 Suppl 2:144.1–144. 2016. View Article : Google Scholar
22	Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP and Taylor PC: Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol. 45:14–21. 2018. View Article : Google Scholar : PubMed/NCBI
23	Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD and Macias WL: Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase iib study of patients with active rheumatoid arthritis. Arthritis Rheumatol. 69:943–952. 2017. View Article : Google Scholar : PubMed/NCBI
24	Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, et al: Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 374:1243–1252. 2016. View Article : Google Scholar : PubMed/NCBI
25	Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, et al: Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 74:333–340. 2015. View Article : Google Scholar : PubMed/NCBI
26	Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH and Dougados M: Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 3:e0004102017. View Article : Google Scholar : PubMed/NCBI
27	Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, et al: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 376:652–662. 2017. View Article : Google Scholar : PubMed/NCBI
28	Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T and Macias W: Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: A 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 43:504–511. 2016. View Article : Google Scholar : PubMed/NCBI
29	Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sánchez Bursón JM, et al: Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 76:694–700. 2017. View Article : Google Scholar : PubMed/NCBI
30	Leonard WJ and O'Shea JJ: Jaks and STATs: Biological implications. Annu Rev Immunol. 16:293–322. 1998. View Article : Google Scholar : PubMed/NCBI
31	Pelletier S, Gingras S, Funakoshi-Tago M, Howell S and Ihle JN: Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function. Mol Cell Biol. 26:8527–8538. 2006. View Article : Google Scholar : PubMed/NCBI
32	Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H, Ida H, et al: Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 31:451–456. 2011. View Article : Google Scholar : PubMed/NCBI
33	Souto A, Salgado E, Maneiro JR, Mera A, Carmona L and Gómez-Reino JJ: Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: A systematic review and meta-analysis. Arthritis Rheumatol. 67:117–127. 2015. View Article : Google Scholar : PubMed/NCBI